Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin

Table 1 Analysis of clinical indexes between the dapagliflozin and control groups in patients with type 2 diabetes mellitus (means ± SD, n = 20)

Parameter	Dapagliflozin	Control	Wilcoxon W	P value
Age	39.80 ± 5.136	39.75 ± 5.990	397.000	0.724
Smoking history	16.55 ± 9.720	10.25 ±11.639	353.000	0.111
Height (m)	1.7670 ± 0.07255	1.7505 ± 0.090	389.000	0.569
Weight (kg)	74.950 ± 8.9176	72.525 ± 6.6718	381.500	0.440
BMI (kg/m2)	24.3695 ± 1.82674	24.014 ± 1.6715	385.00	0.499
Waist circumference (cm)	96.350 ± 2.3402	93.525 ± 5.7502	325.000	0.021
Hip circumference (cm)	96.975 ± 2.4413	99.225 ± 6.4062	398.500	0.755
Waist-hip ratio	0.9937 ± 0.0132391	0.9494 ± 0.04815	308.000	0.006
SBP (mmHg)	124.80 ± 5.297	120.40 ± 5.423	323.500	0.018
DBP (mmHg)	78.85 ± 5.724	77.95 ± 5.969	394.500	0.671
Diabetes course (yr)	2.575 ± 1.2169	2.825 ± 1.8229	396.500	0.713
TG	1.884 ± 1.2172	0.979 ± 0.2376	1.2172203	0.002
LDL	2.8585 ± 1.0440	1.5975 ± 0.5079	1.0439867	< 0.001
HDL	1.0855 ± 0.2457	1.023 ± 0.1246	0.2457100	0.560
APOA1	1.3630 ± 0.2022	1.2625 ± 0.1882	0.2022271	0.010
APOB100	0.9425 ± 0.2651	1.0345 ± 0.1521	0.2651092	0.424
CRP	1.311 ± 0.9305	1.1635 ± 0.5462	0.9305511	0.967
HbA1c	6.7500 ± 0.6863	6.3700 ± 0.3827	0.6863327	0.032
THCY	12.030 ± 2.1451	12.4215 ± 1.2702	2.1450899	0.213
RBP4	37.150 ± 5.6033	35.800 ± 4.3842	5.6033	0.446
NEFA	0.8245 ± 0.5849	1.026 ± 0.1099	0.5849019	< 0.001
FCP	2.2770 ± 0.7903	2.231 ± 0.4151	0.7903104	0.525
TC	4.1950 ± 0.8378	3.7875 ± 0.4683	344.500	0.076
IR	2.7120 ± 1.7245	2.8440 ± .8424	358.500	0.163
FINS	8.4905 ± 4.4824	10.313 ± 3.2099	328.500	0.027
FBP	6.80 ± 1.105	6.15 ± 0.671	335.500	0.034
Non-HDL	3.05 ± 0.826	2.80 ± 0.410	364.000	0.142
HOMA2- insulin	75.6150 ± 20.339	89.460 ± 18.246	324.000	0.020
HOMA2-S%	61.6750 ± 21.1603	60.440 ± 14.789	400.000	0.787
HOMA2-IR	1.8185 ± 0.7285	1.7210 ± 0.3760	399.000	0.766

BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TG: Triglycerides; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; APOA1: Apolipoprotein A1; ApoB100: Apolipoprotein B100; CRP: C-reactive protein; FBG: Fasting blood glucose; HbA1c: Hemoglobin A1c; THCY: Homocysteine; RBP4: Retinol binding protein 4; NEFA: Non-esterified fatty acids; FCP: Fasting C-peptide; TC: Total cholesterol; FINS: Fasting plasma insulin level; HOMA2-B: Homeostatic model assessment-beta cell; HOMA2-S%: Homeostatic model assessment-insulin sensitivity; HOMA2-IR: Homeostatic model assessment-insulin resistance.